Solventum faces earnings test on growth targets after 3M spin-off

robot
摘要生成中

Solventum (SOLV) is under scrutiny as it prepares to release its fourth-quarter earnings, with analysts expecting a 24% increase in earnings per share. The healthcare company, spun off from 3M, aims to demonstrate sustainable growth, particularly eyeing its 4-5% organic growth objective by 2028. Investors will focus on new product launches, dental segment performance, the integration of Acera Surgical, and how the company plans to allocate its capital, including $1 billion authorized for share repurchases.

此页面可能包含第三方内容,仅供参考(非陈述/保证),不应被视为 Gate 认可其观点表述,也不得被视为财务或专业建议。详见声明
  • 赞赏
  • 评论
  • 转发
  • 分享
评论
请输入评论内容
请输入评论内容
暂无评论